Results 231 to 240 of about 94,605 (281)

PBLD Orchestrates the STING‐Mediated Antiviral Immune Response and Autoimmune Diseases

Advanced Science, Volume 13, Issue 4, 19 January 2026.
During viral infection, PBLD expression is downregulated, thereby subverting host antiviral defenses and promoting viral replication. This study identifies PBLD as a positive regulator of STING‐induced type I interferon activation and delineated the molecular network underlying PBLD‐mediated antiviral immunity and autoimmune pathogenesis, highlighting ...
Peili Hou, Hongchao Zhu, Xiaonan Sun, Ni Zhang, Song Wang, Xuexing Zheng, Xiaoyun Wang, Yueyue Feng, Fuzhen Zhang, Xingyu Li, Rui Li, Xiaomeng Wang, Yuanyuan Han, Jun Wang, Chuanhong Wang, Xiaoyang Yao, Hongmei Wang, Hongbin He   +17 more
wiley   +1 more source

Evaluation of ASC as a therapeutic target for Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 1, January 2026.
Abstract Neuroinflammation is increasingly recognized as a central contributor to the pathogenesis and progression of Alzheimer's disease (AD). The apoptosis‐associated speck‐like protein containing a CARD (ASC), encoded by the PYCARD gene, plays a critical role in the formation of multiple inflammasomes, including NLRP3, a key mediator of inflammation
W. Brent Clayton, Joshua A. Kulas, Jiahui Liu, Nidhi Walia, Claudia Rangel‐Barajas, Travis Johnson, Jie Zhang, Kun Huang, Andrew D. Mesecar, Jeffrey L. Dage, Bruce T. Lamb, Alan D. Palkowitz, Timothy I. Richardson   +12 more
wiley   +1 more source

Fluorescence imaging of MALAT1 expression using a Cy5.5-labeled antisense oligonucleotide in lung cancer and epidermal carcinoma cells. [PDF]

Cancer Imaging
Liu Z, Yao C, Ni H, Wang G, Dong M.
europepmc   +1 more source

A splice-switching antisense oligonucleotide targeting APP reduces accumulation of α-synuclein in a mouse model of Parkinson's disease. [PDF]

Alzheimers Dement (N Y)
Ahammad RU, Spencer B, Quach B, Salehi S, Rissman RA.   +4 more
europepmc   +1 more source

Cellular immune changes during severe antisense oligonucleotide-associated thrombocytopenia in a nonhuman primate model. [PDF]

J Immunol
Gupta S, Shen L, Henry SP, Aghaeepour N, Narayanan P, Maecker HT.   +5 more
europepmc   +1 more source

Intra-amniotic antisense oligonucleotide treatment improves phenotypes in preclinical models of spinal muscular atrophy. [PDF]

Sci Transl Med
Borges B, Brown SM, Chen WJ, Clarke MT, Herzeg A, Park JH, Ross J, Kong L, Denton M, Smith AK, Lum T, Zada FM, Cordero M, Gupta N, Cook SE, Murray H, Matson J, Klein S, Bennett CF, Krainer AR, MacKenzie TC, Sumner CJ.   +21 more
europepmc   +1 more source

Customized antisense oligonucleotide-based therapy for neurofilament-associated Charcot-Marie-Tooth disease. [PDF]

Brain
Medina J, Rebelo A, Danzi MC, Jacobs EH, Xu IRL, Ahrens KP, Chen S, Raposo J, Yanick C, Zuchner S, Saporta MA.   +10 more
europepmc   +1 more source

Antisense oligonucleotide allele-specific targeting of EFEMP1 in a patient-derived model of Doyne honeycomb retinal dystrophy

Rezek FO, Sanchez-Pintado B, Eden ER, Aychoua N, Webster AR, Carr AF, Michaelides M, Cheetham ME, van der Spuy J.   +8 more
europepmc   +1 more source